References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2020-4083

russjcardiol-4083

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Хроническая сердечная недостаточность. Клинические рекомендации 2020

2020 Clinical practice guidelines for Chronic heart failure

Российское кардиологическое общество (РКО)

Russian Society of Cardiology (RSC)

tuskach@mail.ru

2020

30112020

251140834083

2020

Российское кардиологическое общество (РКО) ..

Russian Society of Cardiology (RSC) ..

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/4083

Одобрено Научно-практическим Советом Минздрава Российской Федерации.

Endorsed by the Research and Practical Council of the Ministry of Health of the Russian Federation.

хроническая сердечная недостаточностьнатрийуретические пептидыфракция выброса левого желудочкадиагностикамедикаментозная терапиянемедикаментозная терапиясочетанная патологиядекомпенсациягоспитализация критерии качестварекомендации

chronic heart failurenatriuretic peptidesleft ventricular ejection fractiondiagnosticsmedical therapynon-drug therapycomorbiditydecompensationhospitalizationquality criteriaguidelines

References1

Фомин И. В. Артериальная гипертония в Российской Федерации — последние 10 лет. Что дальше? Сердце. 2007;6(3):1-6.

Fomin IV. Arterial hypertension in the Russian Federation-the last 10 years. What's next? Heart. 2007;6(3):1-6. (In Russ.)

Ситникова М.Ю., Юрченко А.В., Лясникова Е.А., и др. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология. 2015;55(10):5-13. doi:10.18565/cardio.2015.10.5-13

Sitnikova MYu, Lyasnikova EA, Yurchenko AV, et al. The results of the Russian hospital register of chronic heart failure in 3 regions of the Russian Federation. Kardiologija. 2015;55(10):5-13. (In Russ.)

Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа. 2010.C. 7-77

Fomin IV. Epidemiology of chronic heart failure in the Russian Federation. In: Chronic heart failure. M.:GEOTAR-Media. 2010. p. 7-77. (In Russ).

Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442-63. doi:10.1016/s0195-668x(02)00823-0.

Lam CSP, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail. 2014;16:1049-55. doi:10.1002/ejhf.159.

Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., и др. Истинная распространенность ХСН в европейской части Российской Федерации (госпитальный этап). Журнал сердечная недостаточность. 2011;12(2):63-8.

Belenkov YuN, Mareev VYu, Ageev FT, et al. The true prevalence of CHF in the European part of the Russian Federation (hospital stage). Zhurnal serdechnaya nedostatochnost. 2011;12(2):63-8. (In Russ.)

Фомин И. В., Бадин Ю. В., Егорова И. С., Щербинина Е. В. Гендерные различия в распространенности сердечно-сосудистых заболеваний (данные когортного исследования репрезентативной выборки Нижегородской области 1998-2002 гг.). Проблемы женского здоровья. 2006;1(1):37-40.

Fomin IV, Badin YuV, Egorova IS, Shcherbinina EV. Gender differences in the prevalence of cardiovascular diseases (data from a cohort study of a representative sample of the Nizhny Novgorod region in 1998-2002). Women's health Problems. 2006;1(1):37-40. (In Russ.)

McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999;138(1 Pt 1):87-94. doi:10.1016/s0002-8703(99)70251-6.

Терещенко С. Н., Жиров И. В., Нарусов О. Ю., Мареев Ю. В., Затейщиков Д. А., Осмоловская Ю. Ф., Овчинников А. Г., Самко А. Н., Насонова С. Н., Стукалова О. В., Саидова М. А., Скворцов А. А., Шария М. А., Явелов И. С. Диагностика и лечение хронической и острой сердечной недостаточности. Кардиологический вестник. 2016;2:3-33.

Tereshchenko SN, Zhirov IV, Narusov OYu, et al. Diagnosis and treatment of chronic and acute heart failure. Cardiological Bulletin. 2016;2:3-33. (In Russ.)

McMurray J. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362(3):228-38. doi:10.1056/NEJMcp0909392.

Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011;306 (15):1669-78. doi:10.1001/jama.2011.1474.

Dunlay SM, Redfield MM, Weston SA, et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009;54(18):1695-702. doi:10.1016/j.jacc.2009.08.019.

Hogg K, Swedberg K, McMurray J. Heart Failure with preserved left ventricular systolic function. Epidemiology, Clinical Characteristics, and Prognosis. J Am Coll Cardiol. 2004;43(3):317-27. doi:10.1016/j.jacc.2003.07.046.

Агеев Ф. Т. Современная концепция диастолической сердечной недостаточности. Кардиоваскулярная терапия и профилактика. 2010;9(7):97-104.

Ageev FT. Modern concept of diastolic heart failure. Cardiovascular Therapy and Prevention. 2010;9(7):97-104. (In Russ.)

Senni M, Gavazzi A, Oliva F, at al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol. 2014;173(2):163-9. doi:10.1016/j.ijcard.2014.02.018.

Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002;23(11):877-85. doi:10.1053/euhj.2001.2973.

Беленков Ю. Н., Овчинников А. Г., Агеев Ф. Т., Сербул В. М. Гипертрофия левого желудочка: роль ренин-ангиотензиновой системы. Кардиоваскулярная терапия и профилактика. 2008;7(2):98-108.

Ageev FT, Ovchinnikov AG, Serbul VM, Belenkov YuN. Left ventricular hypertrophy: reninangiotensin system role. Cardiovascular Therapy and Prevention. 2008;7(2):98-108. (In Russ.)

Овчинников А. Г., Агеев Ф. Т., Свирида О. Н. Патогенетический подход к терапии пациентов с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. Кардиологический вестник. 2011;1:33-9.

Svirida ON, Ovchinnikov AG, Ageev FT. Pathogenetic approach to therapy for patients with chronic heart failure and preserved left ventricular systolic function. Kardiologicheskij Vestnik. 2011;1:33-9. (In Russ.)

Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65-75. doi:10.1093/eurheartj/ehi555.

Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4(1):27-35. doi:10.1161/CIRCHEARTFAILURE.109.932996.

Ketchum ES, Levy WC. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011;54(2):86-96. doi:10.1016/j.pcad.2011.03.003.

Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88(1):107-15. doi:10.1161/01.cir.88.1.107.

Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Влияние терапии на прогноз и выживаемость больных с хронической сердечной недостаточностью. Русский медицинский журнал. 1999;2:9.

Mareev VYu, Danielyan MYu, Belenkov YuN. Effect of therapy on prognosis and survival of patients with chronic heart failure. Russkij Medicinskij Zhurnal. 1999;2:9. (In Russ.)

Фомин И. В. Хрониченская сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. doi:10.15829/1560-4071-2016-8-7-13.

Fomin IV. Chronic heart failure in Russian Federation: What do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13. (In Russ.)

Якушин С. С., Смирнова Е. А., Лиферов Р. А. Выживаемость больных хронической сердечной недостаточностью (данные когортного исследования репрезентативной выборки населения Рязанской области). Сердечная недостаточность. 2011;12 (4):218-21.

Yakushin SS, Smirnova EA, Liferov RA. Survival of patients with chronic heart failure (data from a cohort study of a representative sample of the population of the Ryazan region). Heart failure. 2011;12(4):218-21. (In Russ.)

Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal proB-type natriuretic peptide. Eur J Heart Fail. 2009;11(3):281-91. doi:10.1093/eurjhf/hfn046.

Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11(2):170-7. doi:10.1093/eurjhf/hfn031.

Jackson CE, Solomon SD, Gerstein HC, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009;374(9689):543-50. doi:10.1016/S0140-6736(09)61378-7.

Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007;50(1):40-7. doi:10.1016/j.jacc.2007.02.067.

Беленков Ю. Н., Фомин И. В., Мареев В. Ю. Первые результаты Российского эпидемиологического исследования по ХСН. Журнал Сердечная Недостаточность. 2003;4(1):26-30.

Belenkov YuN, Fomin IV, Mareev VYu, on behalf of researchers. The first results of the Russian epidemiological studies on heart failure. Heart Failure Journal. 2003;4(1):26-30. (In Russ.)

Агеев Ф.Т., Даниелян М. О., Мареев В. Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Журнал Сердечная Недостаточность. 2004;5(1):4-7.

Ageev FT, Danielyan MO, Mareev VY, et al. Patients with chronic heart failure in the Russian ambulatory practice: contingent features, diagnosis and treatment (studies of AGE-O-CHF). Russian Heart Failure Journal. 2004;5(1):4-7. (In Russ.)

Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006;7(1):112-5.

Ageev FT, Belenkov YN, Fomin IV, et al. Prevalence of chronic heart failure in European area of Russian Federation — data from EPOCH-HF. Serdechnaya Nedostatochnost. 2006;7(1):112-5. (In Russ.)

Davie P, Francis CM, Caruana L, et al. Assessing diagnosis in heart failure: which features are any use? QJM. 1997;90:335-9. doi:10.1093/qjmed/90.5.335.

Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data metaanalysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13:1-207. doi:10.3310/hta13320.

Oudejans I, Mosterd A, Bloemen JA, et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail. 2011;13:518-27. doi:10.1093/eurjhf/hfr021.

Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev. 2006;11:95-107. doi:10.1007/s10741-006-9481-0.

Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124:2865-73. doi:10.1161/CIRCULATIONAHA.111.019216.

Weingartner O, Hasan T, Bohm M. Pathophysiology and differential diagnosis of dyspnea Herz. 2004;29(6):595-601. doi:10.1007/s00059-004-2594-0.

Fries R. Differential diagnosis of leg edema. MMW Fortschr Med. 2004;146(16):39-41.

Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606-19. doi:10.1161/HHF.0b013e318291329a.

Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75. doi:10.1161/CIRCULATIONAHA.111.080770.

Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119(24):3070-7. doi:10.1161/CIRCULATIONAHA.108.815944.

Ощепкова Е. В., Лазарева Н. В., Сатлыкова Д. Ф., Терещенко С. Н. Первые результаты Российского регистра хронической сердечной недостаточности. Кардиология. 2015;55(5):22-8. doi:10.18565/cardio.2015.5.22-28

Oshchepkova EV, Lazarev NV, Satlykova DF, Tereschenko SN. The first results of the Russian Register of chronic heart failure. Kardiologiia. 2015;55(5):22-8. (In Russ). doi:10.18565/cardio.2015.5.22-28

Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013; 62(4):263-71. doi:10.1016/j.jacc.2013.02.092.

Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2017;376(9):897. doi:10.1056/NEJMc1615918.

Paulus WJ, Dal Canto E. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. JACC Heart Fail. 2018;6(1):1-7. doi:10.1016/j.jchf.2017.07.012.

Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2014;11(4):354-65. doi:10.1007/s11897-014-0223-7.

Liu M, Fang F, Yu CM. Noncardiac Comorbidities in Heart Failure With Preserved Ejection Fraction — A Commonly Ignored Fact. Circ J. 2015;79(5):954-9. doi:10.1253/circj.CJ-15-0056.

Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591-602. doi:10.1038/nrcardio.2017.65.

Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910. doi:10.1136/bmj.h910.

Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTpro мозговой натрийуретический пептид in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005;7:537-41. doi:10.1016/j.ejheart.2005.01.022.

Fuat A, Murphy JJ, Hungin APS, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56:327-33.

Yamamoto K, Burnett JC, Bermudez EA, et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail. 2000;6:194-200. doi:10.1054/jcaf.2000.9676.

Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-53. doi:10.1016/S0140-6736(97)06031-5.

Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111:274-9. doi:10.1016/s0002-9343(01)00841-5.

Kelder JC, Cramer MJ, Verweij WM, et al. Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail. 2011;17:729-34. doi:10.1016/j.cardfail.2011.04.013.

Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386-91. doi:10.1016/s0735-1097(00)01157-8.

McCullough PA, Duc P, Omland T, et al; Breathing Not Properly Multinational Study Investigators. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the breathing not properly multinational study. Am J Kidney Dis. 2003;41:571-9. doi:10.1053/ajkd.2003.50118.

Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013;34:816-29. doi:10.1093/eurheartj/ehs224.

Jankowska EA Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34:827-34. doi:10.1093/eurheartj/ehs377.

Damman K, Valente MAE, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455-69. doi:10.1093/eurheartj/eht386.

Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J. 2014;35:416-8. doi:10.1093/eurheartj/eht515.

Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep. 2009;6:272-80. doi:10.1007/s11897-009-0037-1.

Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009;54:422-8. doi:10.1016/j.jacc.2009.04.049.

Ewid M, Sherif H, Allihimy AS, et al. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes. 2020;13:178. doi:10.1186/s13104-020-05031-3.

Wannamethee SG, Whincup PH, Shaper AG. Г-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012;32(3):830-5. doi:10.1161/ATVBAHA.111.240457.

Poelzl G, Eberl C, Achrainer H, et al. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail. 2009;2(4):294-302. doi:10.1161/CIRCHEARTFAILURE.108.826735.

Ess M, Mussner-Seeber C, Mariacher S, et al. Y-Glutamyltransferase rather than total bilirubin predicts outcome in chronic heart failure. J Card Fail. 2011;17(7):577-84. doi:10.1016/j.cardfail.2011.02.012.

Yamazoe M, Mizuno A, Nishi Y, et al. Serum alkaline phosphatase as a predictor of worsening renal function in patients with acute decompensated heart failure. J Cardiol. 2016;67(5):412-417. doi:10.1016/j.jjcc.2015.08.004.

Shamban L, Patel B, Williams M. Significantly Elevated Liver Alkaline Phosphatase in Congestive Heart Failure. Gastroenterology Res. 2014;7(2):64-8. doi:10.14740/gr600w.

Rhee CM, Curhan GC, Alexander ER, et al. Subclinical Hypothyroidism and Survival: The Effects of Heart Failure and Race J Clin Endocrinol Metab. 2013;98(6):2326-36. doi:10.1210/jc.2013-1039.

Pingitore A, Landi P, Taddei MC, et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med. 2005;118:132-6. doi:10.1016/j.amjmed.2004.07.052.

Passino C, Pingitore A, Landi P, et al. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure.J Card Fail. 2009;15:35-40. doi:10.1016/j.cardfail.2008.08.008.

Martinez F. Thyroid hormones and heart failure. Heart Failure Reviews. 2016;21:361-4. doi:10.1007/s10741-016-9556-5.

Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;2(11):1933-40. doi:10.1016/j.jacc.2003.07.016.

Cappola A.R., Fried L.P., Arnold A.M. at al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006; 295:1033-1041. doi: 10.10O1/jama.295.9.1033

Greene SJ, Vaduganathan M, Lupi L, et al. Prog nostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol. 2013;111(4):574-81. doi:10.1016/j.amjcard.2012.10.042.

Khunti K, Squire I, Abrams KR, Sutton AJ. Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. Eur J Heart Fail. 2004;6(5):571-6. doi:10.1016/j.ejheart.2004.03.013.

Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312(7025):222. doi:10.1136/bmj.312.7025.222.

Thomas JT, Kelly RF, Thomas SJ, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med. 2002;112:437-45. doi:10.1016/s0002-9343(02)01048-3.

Tribouilloy C, Rusinaru D, Mahjoub H, et al. Impact of echocardiography in patients hospitalized for heart failure: a prospective observational study. Arch Cardiovasc Dis. 2008;101:465-73. doi:10.1016/j.acvd.2008.06.012.

Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol. 2007;50:381-96. doi:10.1016/j.jacc.2007.03.048.

Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol. 1999;33:164-70. doi:10.1016/s0735-1097(98)00523-3.

Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009;15:586-92. doi:10.1016/j.cardfail.2009.03.002.

Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252-89. doi:10.1016/j.jacc.2017.03.011.

Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-39. doi:10.1016/j.echo.2014.07.012.

Porter TR, Shillcutt SK, Adams MS, et al. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2015;28(1):40-56. doi:10.1016/j.echo.2014.09.009.

EchoNoRMAL (Echocardiographic Normal Ranges Meta-Analysis of the Left Heart) Collaboration. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The EchoNoRMAL Study. JACC Cardiovasc Imaging. 2015;8:656-65. doi:10.1016/j.jcmg.2015.02.014.

Muraru D, Badano LP, Peluso D, et al. Comprehensive analysis of left ventricular geometry and function by three-dimensional echocardiography in healthy adults. J Am Soc Echocardiogr. 2013;26:618-28. doi:10.1016/j.echo.2013.03.014.

Kou S, Caballero L, Dulgheru R, et al. Echocardiographic reference ranges for normal cardiac chamber size: results from the NORRE study. Eur Heart J Cardiovasc Imaging. 2014;15:680-90. doi:10.1093/ehjci/jet284.

Alherbish A, Becher H, Alemayehu W, et al. Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography. 2018;35(11):1746-54. doi:10.1111/echo.14152.

Dorosz JL, Lezotte DC, Weitzenkamp DA, et al. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;59:1799-808. doi:10.1016/j.jacc.2012.01.037.

Goldenberg I, Moss AJ, Hall WJ, et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;124(14):1527-36. doi:10.1161/CIRCULATIONAHA.110.014324.

Thavendiranathan P, Liu S, Datta S, et al. Automated quantification of mitral inflow and aortic outflow stroke volumes by three-dimensional real-time volume color-flow Doppler transthoracic echocardiography: comparison with pulsed-wave Doppler and cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 2012;25(1):56-65. doi:10.1016/j.echo.2011.10.004.

Hoffmann R, von Bardeleben S, ten Cate F, et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J. 2005;26(6):607-16. doi:10.1093/eurheartj/ehi083.

Hoffmann R, Barletta G, von Bardeleben S, et al. Analysis of left ventricular volumes and function — a multicenter comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast enhanced 2D and 3D echocardiography. J Am Soc Echocardiogr. 2014;27:292-301. doi:10.1016/j.echo.2013.12.005

Thavendiranathan P, Poulin F, Lim KD, et al. Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review. J Am Coll Cardiol. 2014;63:2751-68. doi:10.1016/j.jacc.2014.01.073.

Mignot A, Donal E, Zaroui A, et al. Global longitudinal strain as a major predictor of cardiac events in patients with depressed left ventricular function: a multicenter study. J Am Soc Echocardiogr. 2010;23:1019-24. doi:10.1016/j.echo.2010.07.019.

Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr. 2013;26:185-91. doi:10.1016/j.echo.2012.10.008.

100

Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2(5):356-64. doi:10.1161/CIRCIMAGING.109.862334.

101

Bansal M, Cho GY, Chan J, et al. Feasibility and accuracy of different techniques of twodimensional speckle based strain and validation with harmonic phase magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21:1318-25. doi:10.1016/j.echo.2008.09.021.

102

Nagueh S, Smiseth O, Appleton C, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277-314. doi:10.1016/j.echo.2016.01.011.

103

Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130-9. doi:10.1093/eurjhf/hfn013.

104

Jolicreur EM, Dunning A, Castelvecchio S, et al. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. J Am Coll Cardiol. 2015;66:2092-100. doi:10.1016/j.jacc.2015.08.882.

105

Tonino PA, De Bruyne B, Pijls NH, et al., Investigators FS. Fractional flow reserve vs. angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360(3):213-24. doi:10.1056/NEJMoa0807611.

106

Toth G, De Bruyne B, Casselman F, et al. Fractional flow reserve-guided vs. angiography-guided coronary artery bypass graft surgery. Circulation. 2013;128(13):1405-11. doi:10.1161/CIRCULATIONAHA.113.002740.

107

Beller GA, Heede RC. SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability. J Cardiovasc Transl Res. 2011;4:416-24. doi:10.1007/s12265-011-9290-2.

108

Beanlands RSB, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-12. doi:10.1016/j.jacc.2007.09.006.

109

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585-94. doi:10.1093/eurheartj/ehv338.

110

Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. J Am Coll Cardiol Img. 2014;7:531-2. doi:10.1016/j.jcmg.2014.03.004.

111

Bokhari S, Castano A, Pozniakoff T, et al. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidosis. Circ Cardiovasc Imaging. 2013;6:195-201. doi:10.1161/CIRCIMAGING.112.000132.

112

Aljaroudi WA, Desai MY, Tang WH, et al. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014;21:271-83. doi:10.1007/s12350-013-9800-5.

113

Saric M, Armour AC, Arnaout MS, et al. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. J Am Soc Echocardiogr. 2016;29(1):1-42. doi:10.1016/j.echo.2015.09.011.

114

Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/ SCAI/SCCM/ SCCT/SCMR 2011 appropriate use criteria for echocardiography. J Am Coll Cardiol. 2011;57:1126-66.

115

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239. doi:10.1016/j.jacc.2013.05.019.

116

Khemka A, Sawada SG. Dobutamine echocardiography for assessment of viability in the current era. Curr Opin Cardiol . 2019;34(5):484-9. doi:10.1097/HCO.0000000000000658.

117

Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6:363-72. doi:10.1161/CIRCIMAGING.112.000138.

118

Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617-25. doi:10.1056/NEJMoa1100358.

119

de Filippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. Am J Cardiol. 1995;75:191-4. doi:10.1016/s0002-9149(00)80078-8.

120

Tribouilloy C, Levy F, Rusinaru D, et al. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am Coll Cardiol. 2009;53:1865-73. doi:10.1016/j.jacc.2009.02.026.

121

Clavel MA, Fuchs C, Burwash IG, et al. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicenter TOPAS Study. Circulation. 2008;118(14 Suppl):S234-42. doi:10.1161/CIRCULATIONAHA.107.757427.

122

Garnier F, Eicher J-C, Jazayeri S, et al. Usefulness and limitations of contractile reserve evaluation in patients with low-flow, low-gradient aortic stenosis eligible for cardiac resynchronization therapy. Eur J Heart Fail. 2014;16:648-54. doi:10.1002/ejhf.78.

123

Erdei T, Smiseth OA, Marino P, Fraser AG. A systematic review of diastolic stress tests in heart failure with preserved ejection fraction, with proposals from the EU-FP7 MEDIA study group. Eur J Heart Fail. 2014;16:1345-61. doi:10.1002/ejhf.184.

124

Donal E, Lund LH, Oger E, et al. Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging 2016;17:106-13. doi:10.1093/ehjci/jev144.

125

Borlaug B Nishimura R, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-95. doi:10.1161/CIRCHEARTFAILURE.109.930701.

126

Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. J Am Coll Cardiol. 2008;52:1724-32. doi:10.1016/j.jacc.2008.07.031.

127

Paech DC, Weston AR. A systematic review of the clinical effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of suspected coronary artery disease. BMC Cardiovasc Disord. 2011;11:32. doi:10.1186/1471-2261-11-32.

128

Goldstein JA, Gallagher MJ, O'Neill WW, et al. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol. 2007;49:863-71. doi:10.1016/j.jacc.2006.08.064.

129

Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med. 2012;367:299-308. doi:10.1056/NEJMoa1201161.

130

Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619. doi:10.1093/eurheartj/ehu278.

131

Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34:2949-3003. doi:10.1093/eurheartj/eht296.

132

Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320

133

Sousa PA, Bettencourt N, Dias Ferreira N, et al. Role of cardiac multidetector computed tomography in the exclusion of ischemic etiology in heart failure patients. Rev Port Cardiol. 2014;33(10):629-36.

134

Hundle WG, Blumke D, Bogaert JG, et al. Society for cardiovascular magnetic resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn reson. 2009;11:5.

135

Kramer C, Barkhausen J, Flamn SD, et al. Standardised cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008;10:35.

136

Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. European heart journal cardiovascular Imaging. 2015;16:14-22.

137

Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896-908.

138

Puntmann VO, Carr-White G, Jabbour A, et al. T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. JACC Cardiovascular imaging. 2016;9:40-50.

139

Kalb B, Indik JH, Ott P, Martin DR. MRI of patients with implanted cardiac devices. J Magn Reson Imaging. 2018;47(3):595-603. doi:10.1002/jmri.25824.

140

Weidman EK, Dean KE, Rivera W, et al. MRI safety: a report of current practice and advancements in patient preparation and screening. Clin Imaging. 2015;39(6):935-7. doi:10.1016/j.clinimag.2015.09.002.

141

Tsai LL, Grant AK, Mortele KJ, et al. A Practical Guide to MR Imaging Safety: What Radiologists Need to Know. Radiographics. 2015;35(6):1722-37. doi:10.1148/rg.2015150108.

142

Sechtem U, Pflugfelder P, Higgins CB. Quantification of cardiac function by conventional and cine magnetic resonance imaging. Cardiovasc Intervent Radiol. 1987;10:365-73. doi:10.1007/BF02577347.

143

Pattynama PM, Lamb HJ, van der Velde EA, et al. Left ventricular measurements with cine and spin-echo MRI imaging: a study of reproducibility with variance component analysis. Radiology. 1993;187:261-8. doi:10.1148/radiology.187.1.8451425.

144

Reichek N. Magnetic resonance imaging for assessment of myocardial function. Magn Reson Q. 1991;7:255-74.

145

Hudsmith LE, Petersen SE, Francis JM, et al. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7:775-82

146

Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:417-26.

147

Maceira AM, Prasad SK, Khan M, Pennell DJ. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J. 2006;27:2879-88.

148

Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American college of cardiology foundation task force on expert consensus documents. Circulation. 2010;121:2462-508.

149

Valsangiocomo Buechel ER, Mertens L. Imaging the right heart: the use of integrated multimodality imaging. Eur Heart J. 2012;33:949-60.

150

Grothues F, Moon J, Bellenger N, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004;147:218-23.

151

Kilner PJ, Geva T, Kaemmerer H, et al. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology. Eur Heart J. 2010;31:794-805.

152

Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep. 2015;12:276-83.

153

Pons-Llado G, Carreras F, Borras X, et al. Bayes de Luna Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. Am J Cardiol. 1997;79:1651-6.

154

Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90:645-9.

155

Fattori R, Biagini E, Lorenzini M, et al. Significance of magnetic resonance imaging in apical hypertrophic cardiomyopathy. Am J Cardiol. 2010;105:1592-159.

156

Ashrith G, Gupta D, Hanmer J, Weiss RM. Cardiovascular magnetic resonance characterization of left ventricular non-compaction provides independent prognostic information in patients with incident heart failure or suspected cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:64.

157

Choi Y, Kim SM, Lee SC, et al. Quantification of left ventricular trabeculae using cardiovascular magnetic resonance for the diagnosis of left ventricular non-compaction: evaluation of trabecular volume and refined semi-quantitative criteria. J Cardiovasc Magn Reson. 2016;18:24.

158

Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461-74.

159

Yoshida A, Ishibashi-Ueda H, Yamada N, et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail. 2013;15:166-75.

160

Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.

161

Abbasi SA, Ertel A, Shah RV, et al. Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance. 2013;15:89.

162

Sobol I, Horn E, Dele-Michael A, et al. 123 Assessment of Unexplained Cardiomyopathy (CMP) — Clinical Utility of Delayed-Enhancement Cardiac Magnetic Resonance (DE-CMR) Compared to Endomyocardial Biopsy. The Journal of Heart and Lung Transplantation. 2012;31(4).S50. doi:10.1016/j.healun.2012.01.127.

163

Karamitsos ThD, Papanastasiou ChA. Cardiac Magnetic Resonance T1 Mapping for Cardiac Amyloidosis: The Best Way Forward. JACC Cardiovasc Imaging. 2019;8:S1936-878X.

164

Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J. Am. Coll. Cardiol. 2008;51:1022-30.

165

Nam BD, Kim SM, Jung HN, et al. Comparison of quantitative imaging parameters using cardiovascular magnetic resonance between cardiac amyloidosis and hypertrophic cardiomyopathy: inversion time scout versus T1 mapping. Int J Cardiovasc Imaging. 2018;34(11):1769-77.

166

Fontana M, Pica S, Reant P, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132:1570-9.

167

Karur GR, Robison S, Iwanochko RM, et al. Use of myocardial T1 mapping at 3.0 T to differentiate Anderson-Fabry disease from hypertrophic cardiomyopathy. Radiology. 2018;288(2):398-406.

168

Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circulation Cardiovascular imaging. 2013;6:392-8.

169

Zhang J, Li Y, Xu Q, et al. Cardiac Magnetic Resonance Imaging for Diagnosis of Cardiac Sarcoidosis: A Meta-Analysis. Can Respir J. 2018;2018:7457369. doi:10.1155/2018/7457369.

170

Leong DP, Chakrabarty A, Shipp N, et al. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. European heart journal. 2012;33:640-8.

171

Leyva F, Foley PW, Chalil S, et al. Cardiac resynchronization therapy guided by late gadolinium enhancement cardiovascular magnetic resonance. Journal of cardiovascular magnetic resonance official journal of the Society for Cardiovascular Magnetic Resonance. 2011;13:29.

172

Leyva F, Taylor RJ, Foley PW, et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. Journal of the American College of Cardiology. 2012;60:1659-67.

173

Daoulah A, Alsheikh-Ali AA, Al-Faifi SM, et al. Cardiac resynchronization therapy in patients with postero-lateral scar by cardiac magnetic resonance: A systematic review and metaanalysis. J Electrocardiol. 2015;48(5):783-90. doi:10.1016/j.jelectrocard.2015.06.012.

174

Acosta J, Fernandez-Armenta J, Borras R, et al. Scar Characterization to Predict LifeThreatening Arrhythmic Events and Sudden Cardiac Death in Patients With Cardiac Resynchronization Therapy: The GAUDI-CRT Study. JACC Cardiovasc Imaging. 2018;11(4):561-72. doi:10.1016/j.jcmg.2017.04.021.

175

Hoke U, Khidir MJ, van der Geest RJ, et al. Relation of Myocardial Contrast-Enhanced T1 Mapping by Cardiac Magnetic Resonance to Left Ventricular Reverse Remodeling After Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy. Am J Cardiol. 2017;119(9):1456-62. doi:10.1016/j.amjcard.2017.01.023.

176

Nguyen UC, Mafi-Rad M, Aben JP, et al. A novel approach for left ventricular lead placement in cardiac resynchronization therapy: Intraprocedural integration of coronary venous electroanatomic mapping with delayed enhancement cardiac magnetic resonance imaging. Heart Rhythm. 2017;14(1):110-9. doi:10.1016/j.hrthm.2016.09.015.

177

Kockova R, Sedlacek K, Wichterle D, et al. Cardiac resynchronization therapy guided by cardiac magnetic resonance imaging: A prospective, single-centre randomized study (CMR-CRT). Int J Cardiol. 2018;270:325-30.

178

Iles L, Pfluger H, Lefkovits L, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. Journal of the American College of Cardiology. 2011;57:821-8.

179

Disertori M, Rigoni M, Pace N, et al. Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction. A meta-analysis. J Am Coll Cardiol Img. 2016;9:1046-55.

180

Roes SD, Borleffs CJ, van der Geest RJ, et al. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmias in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging. 2009;2:183-90.

181

Demirel F, Adiyaman A, Timmer JR, et al. Myocardial scar characteristics based on cardiac magnetic resonance imaging is associated with ventricular tachyarrhythmia in patients with ischemic cardiomyopathy. Int J Cardiol. 2014;177:392-9.

182

Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis. Eur J Heart Fail. 2013;15:1019-27.

183

SOLVD Investigators; Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302. doi:10.1056/NEJM199108013250501.

184

Velazquez EJ, Morrow DA, DeVore AD, et al; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539-48. doi:10.1056/NEJMoa1812851. Erratum in: N Engl J Med. 2019;380(11):1090.

185

Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril,or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906.

186

Maggioni AP, Anand I, Gottlieb SO, et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme inhibitors. J Am Coll Cardiol. 2002;40(8):1414-21.

187

Dimopoulos K, Saukhe TV, Coats A, et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol. 2004;93(2-3):105-11.

188

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316 (23):1429-35.

189

Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273(18):1450-6.

190

Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation.1999;100(23):2312-8.

191

Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-77.

192

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med. 1992;327(10):685-91.

193

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342(8875):821-8.

194

Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-45.

195

Pflugfelder PW, Baird MG, Tonkon MJ, et al. Clinical consequences of angiotensinconverting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol. 1993;22(6):1557-63. doi:10.1016/0735-1097(93)90578-o.

196

Widimsky J, Kremer HJ, Jerie P, Uhhr O. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol. 1995;49(1-2):95-102. doi:10.1007/BF00192366.

197

Erhardt L, MacLean A, Ilgenfritz J, et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995;16(12):1892-9. doi:10.1093/oxfordjournals.eurheartj.a060844.

198

McMurray JJ, Packer M, Desai AS, et al., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.

199

Packer M, Bristow MR, Cohn JN, et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334 (21):1349-55.

200

Gattis WA, O'Connor CM, Leimberger JD, et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91(2):169-74.

201

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353(9146):9-13.

202

Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001;357:1385-90.

203

Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: Betablocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30(18):2186-92.

204

Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.

205

Zannad F, McMurray JJ, Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11-21.

206

Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-51.

207

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.

208

Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials. Int J Cardiol. 2002;82:149-58.

209

Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2:CD003838.

210

Dormans TP, van Meyel JJ, Gerlag PG, et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28(2):376-82.

211

Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57(6):601-9.

212

Patterson JH, Adams KFJr, Applefeld MM, et al. for the Torasemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994;14 (5):514-21.

213

Brater D. Torasemid: pharmacokinetic and clinical efficacy. Eur J Heart Fail. 2001;3(Suppl G):19-24.

214

Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4(4):507-13.

215

Fortuno A, Muniz P, Ravassa S, et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension.1999;34(1):138-43.

216

Yamato M, Sasaki T, Honda K, et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67(5):384-90.

217

Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM — Alternative trial. Lancet. 2003;362(9386):772-6. doi:10.1016/S0140-6736(03)14284-5.

218

Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75.

219

McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensinconvertingenzyme inhibitors: the CHARM — Added trial. Lancet. 2003;362(9386):767-71. doi:10.1016/S0140-6736(03)14283-3.

220

Bohm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102:11-22.

221

Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85.

222

Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59:1938-45.

223

Fox K, Komajda KM, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34(29):2263-70. doi:10.1093/eurheartj/eht101.

224

Hobbs RE. Digoxin's effect on mortality and hospitalization in heart failure: implications of the DIG study. Digitalis Investigation Group. Cleve Clin J Med. 1997;64(5):234-7. doi:10.3949/ccjm.64.5.234.

225

Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34 (20):1489-97.

226

Jorge E, Baptista R, Martins H, et al. Digoxin in advanced heart failure patients: a question of rhythm. Rev Port Cardiol. 2013;32(4):303-10.

227

Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15(5):551-9.

228

Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-8.

229

Adams KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46 (3):497-504.

230

Malik A, Masson R, Singh S, et al. Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology Aug. 2019;74(5):617-27. doi:10.1016/j.jacc.2019.05.064.

231

The GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-30.

232

Lucas M, Kimmig M, Karalis G. Do omega-3 polyunsaturated fatty acids prevent cardiovascular disease? A review of the randomized clinical trials. Lipid Insights. 2013;6:13-20.

233

Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314(24):1547-52.

234

Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-57.

235

Carson P, Ziesche S, Johnson G, Cohn JN, for the Vasodilator — Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5(3):178-87.

236

Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. Eur J Heart Fail. 2005;7(6):1059-69.

237

Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-9.

238

Homma S, Thompson JL, Pullicino PM, et al, WARCEF Investigators.Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366(20):1859-69.

239

Zannad F, Anker SD, Byra WM, et al; COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018;379(14):1332-42. doi:10.1056/NEJMoa1808848.

240

Sulaica EM, Macaulay TE, Helbing RR, et al. A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(2):207-16. doi:10.1007/s10741-019-09818-w.

241

Gheorghiade M, Bohm M, Greene SJ, et al.; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125-35.

242

Parving HH, Brenner BM, McMurray JJ, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-13.

243

Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31:824-31.

244

Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115-28.

245

Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30:2773-8.

246

Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:52-60.

247

Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator — Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96(3):856-63.

248

Thackray S, Witte K, Clark AL, Cleland JG. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail. 2000;2(2):209-12.

249

Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107-14.

250

Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart. 2006;92:1610-5.

251

The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppressionafter myocardial infarction. N Engl J Med. 1989;321(6):406-12.

252

Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-8.

253

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016;37:2129-200. doi:10.1093/eurheartj/ehw128.

254

Cleland JGF, Calvert M, Freemantle N, et al. The heart failure revascularization trial (HEART). Eur J Heart Fail. 2011;13:227-33.

255

Velazquez EJ, Lee KL, Deja MA, et al, STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607-16.

256

Panza JA, Holly TA, Asch FM, et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2013;61:1860-70.

257

Carson P, Wertheimer J, Miller A, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Fail. 2013;1:400-8.

258

Packer M. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002;106:2194-9.

259

Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.

260

Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990-7. doi:10.1093/eurheartj/ehv186.

261

Wyse D, Friedman PL, Epstein AE. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-83.

262

Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8.

263

Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-302.

264

Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-54.

265

Oseroff O, Retyk E, Bochoeyer A. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr Opin Cardiol. 2004;19:26-30.

266

Al-Khatib SM, Sanders GD, Mark DB, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J. 2005;149(6):1020-34. doi:10.1016/j.ahj.2005.02.005.

267

Shen L, Jhund PS, Petrie MC, et al. Declining risk of sudden death in heart failure. N Engl J Med. 2017;377:41-51. doi:10.1056/NEJMoa1609758.

268

Lafuente-Lafuente C, Valembois L, Bergmann J-F, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049.

269

Increased mortality after dronedarone therapy for severe heart failure, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). Eur Heart J. 1992;13:1251-8.

270

Kober L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-87.

271

Koplan BA, Kaplan AJ, Weiner S, et al. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol. 2009;53(4):355-60. doi:10.1016/j.jacc.2008.09.043.

272

Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.

273

Torp-Pedersen C. Metra M, Spark P, et al. The safety of amiodarone in patients with heart failure. J Card Fail. 2007;13:340-5.

274

Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77-82.

275

Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012;9:1465-72.

276

Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865-9.

277

Ban JE, Park HC, Park JS, et al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. Europace. 2013;15:735-41.

278

Chatterjee S, Ghosh J, Lichstein E, et al. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol. 2012;110:607-13.

279

Atti V, Vuddanda V, Turagam MK, et al. Prophylactic catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. J Interv Card Electrophysiol. 2018;53(2):207-15. doi:10.1007/s10840-018-0376-5.

280

Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and metaanalysis of randomized controlled trials. Heart Rhythm. 2016;13(7):1552-9. doi:10.1016/j.hrthm.2016.03.004.

281

Connolly SJ, Dorian P, Roberts RS, et al; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165-71. doi:10.1001/jama.295.2.165.

282

Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. 2014;129:728-36.

283

Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol. 1993;4:253-62.

284

Caceres J, Jazayeri M, McKinnie J, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation. 1989;79:256-70.

285

Proietti R, Essebag V, Beardsall J, et al. Substrate-guided ablation of haemodynamically tolerated and untolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. Europace. 2015;17:461-7.

286

Tchou P, Jazayeri M, Denker S, et al. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation. 1988;78:246-57.

287

Tzou WS, Tung R, Frankel DS, et al. Ventricular Tachycardia Ablation in Severe Heart Failure: An International Ventricular Tachycardia Ablation Center Collaboration [published correction appears in Circ Arrhythm Electrophysiol. 2018;11(8):e000029]. Circ Arrhythm Electrophysiol. 2017;10(1):e004494. doi:10.1161/CIRCEP.116.004494.

288

Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72.

289

Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.

290

Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500-10.

291

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.

292

Connolly SJ, Ezekowitz MD, Yusuf S, et al., RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.

293

Granger CB, Alexander JH, McMurray JJ, et al, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92.

294

Patel MR, Mahaffey KW, Garg J, et al, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.

295

Giugliano RP, Ruff CT, Braunwald E, et al., Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104.

296

Xiong Q, Lau YC, Senoo K, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and metaanalysis of randomized trials. Eur J Heart Fail. 2015;17:1192-200.

297

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-62.

298

Wallentin L, Yusuf S, Ezekowitz MD, et al, RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-83.

299

Pedersen OD, Bagger H, K0ber L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-80.

300

Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86-92.

301

McMurray J, K0ber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction. J Am Coll Cardiol. 2005;45:525-30.

302

Swedberg K, Zannad F, McMurray JJV, et al. Eplerenone and atrial fibrillation in mild systolic heart failure. J Am Coll Cardiol. 2012;59:1598-603.

303

Han M, Zhang Y, Sun S, et al. Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation. J Cardiovasc Pharmacol. 2013;62:405-15.

304

Brodsky MA, Allen BJ, Walker CJ, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol. 1987;60:572-75.

305

Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98:2574-9.

306

Shelton RJ, Clark AL, Goode K, et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart 2009;95:924-30.

307

Capucci A, Villani GQ, Aschieri D, et al. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J. 2000;21:66-73.

308

Hofmann R, Steinwender C, Kammler J, et al. Effects of a high dose intravenous bolus amiodarone in patients with atrial fibrillation and a rapid ventricular rate. Int J Cardiol. 2006;110:27-32.

309

Hofmann R, Wimmer G, Leisch F. Intravenous amiodarone bolus immediately controls heart rate in patients with atrial fibrillation accompanied by severe congestive heart failure. Heart. 2000;84:635.

310

Hagens VE, Crijns HJGM, Van Veldhuisen DJ, et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J. 2005;149:1106-11.

311

Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40.

312

Van Gelder IC, Wyse DG, Chandler ML, et al., RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8:935-42.

313

Li S-J, Sartipy U, Lund LH, et al. Prognostic significance of resting heart rate and use of b-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. Circ Heart Fail. 2015;8:871-9.

314

Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control In. J Fam Practice. 2000; 49:47-59.

315

Kotecha D, Holmes J, Krum H, et al. Efficacy of в blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235-43.

316

Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451.

317

Sethi NJ, Nielsen EE, Safi S, et al. Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS One. 2018;13(3):e0193924. doi:10.1371/journal.pone.0193924.

318

Doshi RN, Daoud EG, Fellows C, et al. PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005;16:1160-5.

319

Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J. 2002;144(4):597-607.

320

Marrouche NF, Brachmann J, Andresen D, et al.; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378:417-27.

321

Packer DL, Mark DB, Robb RA, et al.; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261-74. doi:10.1001/jama.2019.0693.

322

Mark DB, Anstrom KJ, Sheng S, et al.; CABANA Investigators. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. [published correction appears in JAMA. 2019;321(23):2370]. JAMA. 2019;321(13):1275-85. doi:10.1001/jama.2019.0692.

323

Chen C, Zhou X, Zhu M, et al. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. J Interv Card Electrophysiol. 2018;52:9-18.

324

Cleland JG, Keshavarzi F, Pellicori P, Dicken B. Case selection for cardiac resynchronization in atrial fibrillation. Heart Fail Clin. 2013;9:461-74.

325

Brignole M, Pokushalov E, Pentimalli Fet al.; APAF-CRT Investigators. A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J. 2018;39:3999-4008.

326

Bohm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017,38(15):1132-43. doi:10.1093/eur-heartj/ehw570.

327

Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8.

328

MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR / XL Randomized International Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7.

329

Schmieder RE, Rockstroh JK. Efficacy and tolerance of low-dose loop diuretics in hypertension. Cardiology. 1994;84,Suppl 2:36-42.

330

Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung. 1988;38(1A):190-3.

331

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 — effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens. 2018;36(8):1637-47. doi:10.1097/HJH.0000000000001777.

332

Packer M, Carson P, Elkayam U, et al. Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy. JACC: Heart Failure. 2013;1(4):308-14. doi:10.1016/j.jchf.2013.04.004.

333

Physicians Desk Reference. 47th ed. Montvale. NJ: Medical Economics Company. 1993:2250.

334

Cohn JN, Pfeffer MA, Rouleau J, et al, MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-67.

335

ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA. 2000;283:1967-75.

336

Dorszewski A, Gohmann E, Dorszewski B, et al. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. J Card Fail. 1997;3:91-6.

337

Bayliss J, Norell MS, Canepa-Anson R, et al. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. Br Med J (Clin Res Ed). 1985;290:1861-5.

338

Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61.

339

Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807-16. doi:10.1016/S0140-6736(08)61170-8.

340

Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337-45.

341

Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-10.

342

Vitale C, Spoletini I, MalorniW, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina — the VASCO-angina study. Int J Cardiol. 2013;168:1078-81.

343

Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25:1814-21.

344

Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. Heart. 2011;97:278-86.

345

Pursnani S, Korley F, Gopaul R, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv. 2012;5:476-90.

346

Panza JA, Holly TA, Asch FM, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373:911-8.

347

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-28. doi:10.1056/NEJMoa1504720.

348

Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovascular Diabetology. 2016;15(1). doi:10.1186/s12933-016-0356-y.

349

Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation. 2018;138:458-68.

350

Masoudi FA. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study. Circulation. 2005;111(5):583-90. doi:10.1161/01.CIR.0000154542.13412.B1.

351

Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345-51.

352

MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U. K. General Practice Research Database. Diabetes Care. 2010;33:1213-8.

353

Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9:e1001204.

354

Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.

355

Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-42.

356

Rosenstock J, Perkovic V, Johansen OE, et al; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69-79.

357

Holman RR, Bethel MA, Mentz RJ, et al.; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-39.

358

Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22.

359

Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 2247-57.

360

Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44.

361

Husain M, Birkenfeld AL, Donsmark M, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med; doi:10.1056/NEJMoa1901118.

362

Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-30.

363

Jorsal A, Kistorp C, Holmager P, et al L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, doubleblind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69-77.

364

Margulies KB, Hernandez AF, Redfield MM, et al; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500-8.

365

Hawkins NM, Macdonald MR, Petrie MC, et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009;11:684-90.

366

Lainscak M, Podbregar M, Kovacic D, et al. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med. 2011;105, Suppl. 1:S44-S49.

367

Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55(17):1780-7. doi:10.1016/j.jacc.2010.01.024.

368

Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566. doi:10.1002/14651858.CD003566.pub2.

369

Dungen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13(6):670-80. doi:10.1093/eurjhf/hfr020.

370

Tavazzi L, Swedberg K, Komajda M, et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study. International Journal of Cardiology. 2013;170(2):182-8. doi:10.1016/j.ijcard.2013.10.068.

371

Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368:1210-9.

372

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-68.

373

Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-48.

374

Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89:635-41.

375

Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-14.

376

Glassman AH. Cardiovascular Effects of Tricyclic Antidepressants. Annual Review of Medicine. 1984;35(1):503-11. doi:10.1146/annurev.me.35.020184.002443.

377

Pacher P, Ungvari Z, Nanasi PP, et al. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6(6):469-80.

378

Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441(3):137-40.

379

Gelbrich G, Stork S, KreiBl-Kemmer S, et al. Effects of structured heart failure disease management on mortality and morbidity depend on patients' mood: results from the Interdisciplinary Network for Heart Failure Study: Effects of structured HF management depend on patients' mood. Eur J Heart Fail. 2014;16(10):1133-41. doi:10.1002/ejhf.150.

380

Anker SD, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials. 2011;12(1). doi:10.1186/1745-6215-12-194.

381

de la Porte PWFB-A, Lok DJA, van Veldhuisen DJ, et al. Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. Heart. 2007;93(7):819-25. doi:10.1136/hrt.2006.095810.

382

Tu R-H, Zeng Z-Y, Zhong G-Q, et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials: Effects of exercise training on depression in HF: a systematic review. Eur J Heart Fail. 2014;16(7):749-57. doi:10.1002/ejhf.101.

383

Беграмбекова Ю. Л., Мареев В. Ю., Дробижев М. Ю. Школы для пациентов с сердечной недостаточностью. Есть ли ШАНС повлиять на депрессию и тревогу? Вторичный (Post-hoc) анализ исследования ШАНС (Школа и Амбулаторное Наблюдение больных Сердечной недостаточностью). Журнал Сердечная Недостаточность. 2016;17(6):433-42. doi:10.18087/rhfj.2016.6.2281.

Begrambekova YuL, Mareev VYu, Drobizhev MYu. Disease management programs for the heart failure patients. Is there any chance to defeat depression and anxiety post-hoc analysis of chance trial (congestive heart failure: a multidisciplinary non-pharmacological approach for changing in re-hospitalization. Russian Heart Failure Journal. 2016;17(6):433-42. (In Russ.)

384

O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure. Journal of the American College of Cardiology. 2010;56 (9):692-9. doi:10.1016/j.jacc.2010.03.068.

385

Angermann CE, Gelbrich G, Stork S, et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315(24):2683. doi:10.1001/jama.2016.7635.

386

Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch. Intern. Med. 2002;(162):1682-8.

387

Seo WW, Park JJ, Park HA, et al. Guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a cohort study. BMJ Open. 2020;10(2):e030514. doi:10.1136/bmjopen-2019-030514.

388

Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39:26-35.

389

Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20:1230-9.

390

Solomon SD, Claggett B, Lewis EF, et al; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455-62.

391

Solomon SD, McMurray JJV, Anand IS, et al; PARAGON-HF Investigators and Committees. N Engl J Med. 2019;381(17):1609-20. doi:10.1056/NEJMoa1908655.

392

Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397-403. doi:10.1161/CIRCULATIONAHA.106.628347.

393

Azizova AG, Ovchinnikov AG, Blankova ZN, Ageev FT. In patients with elevated LV filling pressure loop diuretics improve severity of heart failure and diastolic dysfunction, but torasemide does it somewhat better than furosemide. Eur J Heart Fail. 2011;10(Suppl 2):S186.

394

Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014 Nov;7(6):935-44. doi:10.1161/CIRCHEARTFAILURE.113.001229.

395

Flather MD, Shibata MC, Coats AJS, et al, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.

396

Mulder BA, van Veldhuisen DJ, Crijns HJGM, et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. Eur J Heart Fail. 2012;14:1171-8.

397

van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2009;53:2150-8.

398

Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-92.

399

Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81.

400

Hernandez AF, Hammill BG, O'Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53(2):184-92.

401

Martin N, Manoharan K, Thomas J, et al. Beta-blockers and inhibitors of the reninangiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev. 2018;6:CD012721.

402

Solomon SD, Vaduganathan M, Claggett BL, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020;141(5):352-61. doi:10.1161/CIRCULATIONAHA.119.044586.

403

Hage F, Hage A, Haddad H, Kiaii B. Update on revascularization in patients with heart failure and coronary artery disease. Curr Opin Cardiol. 2018;33(2):232-6. doi:10.1097/HCO.0000000000000483.

404

Velazquez EJ, Lee KL, Jones RH, et al.; STICHES Investigators. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511-20.

405

Wrobel K, Stevens SR, Jones RH, et al. Influence of baseline characteristics, operative conduct, and postoperative course on 30-day outcomes of coronary artery bypass grafting among patients with left ventricular dysfunction: Results from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. Circulation. 2015;132:720-30.

406

Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-70.

407

Bangalore S, Guo Y, Samadashvili Z, et al. Revascularization in patients with multivessel coronary artery disease and severe left ventricular systolic dysfunction: Everolimus-eluting stents versus coronary artery bypass graft surgery. Circulation. 2016;133:2132-40.

408

Wolff G, Dimitroulis D, Andreotti F, et al. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: A meta-analysis. Circ Heart Fail. 2017;10:e003255.

409

Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39(7):1151-8.

410

Michler RE, Rouleau JL, Al-Khalidi HR, et al, STICH Trial Investigators. Insights from the. STICH trial: Change in left ventricular size after coronary artery bypass grafting . with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg. 2013;146:1139-45.e6

411

Jones RH, Velazquez EJ, Michler RE, et al, STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705-17.

412

Dor V, Civaia F, Alexandrescu C, et al. Favorable effects of . left ventricular reconstruction in patients excluded from the Surgical . Treatments for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2011;141:905-16, 916 e1-e4.

413

Oh JK, Velazquez EJ, Menicanti L, et al, STICH Investigators. Influence of baseline left ventricular . function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. Eur Heart J. 2013;34:39-47.

414

Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-80.

415

Cleland J, Daubert J, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.

416

Cleland JGF, Daubert J-C, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronizationHeart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27:1928-32.

417

Cleland JGF, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization — Heart Failure (CARE-HF) trial. Eur J Heart Fail. 2012;14:628-34.

418

Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50.

419

Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547-56.

420

Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385-95.

421

Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.

422

Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014;370:1694-701.

423

Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-43.

424

Daubert C, Gold MR, Abraham WT, et al, REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE trial. J Am Coll Cardiol. 2009;54:1837-46.

425

Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34:2592-9.

426

Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart. 2015;101:1800-6.

427

Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585-93.

428

Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32:2420-9.

429

Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J. 2002;23:1780-7.

430

Stavrakis S., Garabelli P., Reynolds D.W. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace 2012;14:1490-1497

431

MacDonald MR, Connelly DT, Hawkins NM, et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart. 2011;97:740-7.

432

Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61:1894-903.

433

Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2008;52:1239-46.

434

Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail. 2013;1:500-7.

435

Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail. 2014;16:1199-205.

436

Funck RC, Mueller H-H, Lunati M, et al. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace. 2014;16:354-62.

437

Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395-405.

438

Steffel J, Robertson M, Singh JP, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015;36:1983-9.

439

Zusterzeel R, Selzman KA, Sanders W, et al. Cardiac resynchronization therapy in women:US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med. 2014;174:1340-8.

440

Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.

441

Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874-9.

442

Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverterdefibrillators. N Engl J Med. 2005;353:1471-80.

443

Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverterdefibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-8

444

Teinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427-36.

445

Steinberg BA, AlKhatib SM, Edwards R, et al. Outcomes of implantable cardioverterdefibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail. 2014;2:623-9.

446

Raphael CE, Finegold JA, Barron AJ, et al. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? Eur Heart J. 2015;36:1676-88.

447

Miller RJH, Howlett JG, Exner DV, et al. Baseline functional class and therapeutic efficacy of common heart failure interventions: a systematic review and meta-analysis. Can J Cardiol. 2015;31:792-9.

448

Merchant FM, Jones P, Wehrenberg S, et al. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. J Am Heart Assoc. 2014;3:e001289.

449

Yap S-C, Schaer BA, Bhagwandien RE, et al. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart. 2014;100:1188-92.

450

Kini V, Soufi MK, Deo R, et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol. 2014;63:2388-94.

451

Erkapic D, Sperzel J, Stiller S, et al. Long-term benefit of implantable cardioverter/ defibrillator therapy after elective device replacement: Results of the INcidence free SUrvival after ICD REplacement (INSURE) trial — a prospective multicentre study. Eur Heart J. 2013;34:130-7.

452

Alsheikh-Ali AA, Homer M, Maddukuri PV, et al. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19:784-9.

453

Leon Salas B, Trujillo-Martm MM, Garda Garda J, et al. Subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death: A meta-analysis. Pacing Clin Electrophysiol. 2019. doi: 10.1111/pace.13774.

454

Abraham WT, Kuck KH, Goldsmith RL, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018;6:874-83.

455

Abraham WT, Nademanee K, Volosin K, et al; FIX-HF-5 Investigators and Coordinators. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail. 2011;17(9):710-7. doi:10.1016/j.cardfail.2011.05.006.

456

Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161(2):329-37.e1-2. doi:10.1016/j.ahj.2010.10.025.

457

Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29(8):1019-28. doi:10.1093/eurheartj/ehn020.

458

Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the HeartMate 1000 ip left ventricular assist device. Ann Thorac Surg. 1992;53:1080-90.

459

Gustafsson F, Shaw S, Lavee J, et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. Eur Heart J. 2018;39(37):3454-60. doi:10.1093/eurheartj/ehy513.

460

Jorde UP, Kushwaha SS, Tootles AJ, et al. Results of the destination therapy post-food and drug dministration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2014;63:1751-7.

461

Kirklin JK, Naftel DC, Kormos RL, et al. Interagency registry for mechanically assisted circulatory support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2014;33:12-22.

462

Mehra MR, Salerno C, Cleveland JC, et al. Health Care Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study: A Randomized Controlled Trial of a Magnetically Levitated Cardiac Pump in Advanced Heart Failure. Circulation. 2018;138(18):1923-34. doi:10.1161/CIRCULATIONAHA.118.035722.

463

Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Ventricular Assist DeviceFinal Report. N Engl J Med. 2019;380(17):1618-27. doi:10.1056/NEJMoa1900486.

464

Netuka I, Sood P, Pya Y, et al. Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study. J Am Coll Cardiol. 2015;66(23):2579-89. doi:10.1016/j.jacc.2015.09.083.

465

Rose EA, Moskowitz AJ, Packer M, et al. The rematch trial: Rationale, design, and end points. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure. Ann Thorac Surg. 1999;67:723-30.

466

Schmitto JD, Hanke JS, Rojas SV, et al. First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate III). J Heart Lung Transplant. 2015;34:858-60.

467

Starling RC, Estep JD, Horstmanshof DA, et al; ROADMAP Study Investigators (2017). Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. JACC Heart Fail. 2017;5:518-27.

468

O'Connor CM, Whellan DJ, Lee KL, et al., HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439-50

469

Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014;4:CD003331.

470

Nolte K, Herrmann-Lingen C, Wachter R, et al. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol. 2015;22:582-93.

471

Ismail H, McFarlane JR, Nojoumian AH, et al. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2013;1:514-22.

472

Piepoli MF, Conraads V, Corra U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail. 2011;13:347-57.

473

Wang MH, Yeh ML. Respiratory training interventions improve health status of heart failure patients: A systematic review and network meta-analysis of randomized controlled trials. World J Clin Cases. 2019;7(18):2760-75.

474

Adamopoulos S, Schmid J-P, Dendale P, et al. Combined aerobic/inspiratory muscle training vs. aerobic training in patients with chronic heart failure: The Vent-HeFT trial: a European prospective multicentre randomized trial. European Journal of Heart Failure. 2014;16(5):574-82. doi:10.1002/ejhf.70.

475

Feltner C, Jones CD, Cene CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann Intern Med. 2014;160:774-84.

476

McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44:810-9.

477

Phillips CO, Wright SM, Kern DE, et al. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291:1358-67.

478

Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med. 1999;159:257-61.

479

Schou M, Gustafsson F, Videbaek L, et al. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). Eur Heart J. 2013;34:432-42.

480

Luttik MLA, Jaarsma T, van Geel PP, et al. Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study. Eur J Heart Fail. 2014;16:1241-8.

481

Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16.

482

Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015;17:501-9.

483

Nieminen M, Brutsaert D, Dickstain K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27(22):2725-36.

484

Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296(18):2217-26.

485

Арутюнов А. Г., Рылова А. К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал сердечная недостаточность. 2014;15(1):23-32.

Arutyunov AG, Rylova AK, Arutyunov GP. Registry of hospitalized patients with circulatory decompensation (Pavlov Registry). Report 1. Current clinical characteristics of a patient with circulatory decompensation. Clinical phenotypes of patients. Russian Heart Failure Journal. 2014;15(1):23-32. (In Russ.)

486

Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med. 2003;114(8):625-30.

487

O'Connor CM, Stough WG, Gallup DS, et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail. 2005;11(3):200-5.

488

Valente MA, Voors AA, Damman K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35:1284-93.

489

Shepperd S, McClaran J, Phillips CO, et al. Discharge planning from hospital to home. Cochrane Database Syst Rev. 2010;(1):CD000313.

490

Bielecka-Dabrowa A, Godoy B, Schefold JC, et al. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence? Curr Heart Fail Rep. 2018;15(4):224-38.

491

Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensityscoring methods. Intensive Care Med. 2011;37:290-301.

492

Фомин И. В., Краием Н., Поляков Д. С., и др. Понятие стабильности течения ХСН — приемлемо ли оно для российской практики? Кардиология. 2018;58(S3):55-63.

Fomin IV, Kraiem N, Polyakov DS, et al. The notion of CHF course stability: Is it acceptable for Russian practice? Kardiologiia. 2018;58(S3):55-63. (In Russ.)

493

Stewart S. Financial aspects of heart failure programs of care. Eur J Heart Fail. 2005;7:423-8.

494

Shafie AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev. 2018;23(1):131-45.

495

McAlister FA, Lawson FM, Teo KK, et al. A systematic review of randomized trials of disease management programs in heart failure. Am J Med. 2001;110:378-84.

496

Виноградова Н.Г., Жиркова М.М., Фомин И.В., Поляков Д.С. Эффективность лечения хронической сердечной недостаточности на амбулаторном этапе в условиях городского центра ХСН. Журнал сердечная недостаточность. 2017;18(4):270-8.

Vinogradova NG, Zhirkova MM, Fomin IV, Polyakov DS. Efficacy of therapy for chronic heart failure at the outpatient stage in the conditions of a municipal center for CHF. Russian Heart Failure Journal. 2017;18(4):270-8. (In Russ.)

497

Фомин И.В., Виноградова Н.Г., Фарзалиев М. И., и др. Эффективность наблюдения пациентов в условиях специализированного центра лечения хронической сердечной недостаточности. Неотложная кардиология и кардиоваскулярные риски. 2018;2(1):221-9.

Fomin IV, Vinogradova NG, Farzaliev MI, et al. Effectiveness of patient monitoring in a specialized center for the treatment of chronic heart failure. Emergency cardiology and cardiovascular risks. 2018;2(1):221-9. (In Russ.)

498

Виноградова Н.Г., Поляков Д.С., Фомин И.В., Жиркова М.М. Прогноз жизни пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий в зависимости от контроля гемодинамических показателей и толерантности к физической нагрузке на фоне базисной терапии. Кардиология. 2019;59(4S):51-8.

Vinogradova NG, Polyakov DS, Fomin IV, Zhirkova MM. Prognosis of the life of patients with chronic heart failure and atrial fibrillation, depending on the control of hemodynamic parameters and tolerance to physical exertion in the background of basic therapy. Kardiologiia. 2019;59(4S):51-8. (In Russ.)

499

Виноградова Н. Г. Городской центр лечения хронической сердечной недостаточности: организация работы и эффективность лечения пациентов с хронической сердечной недостаточностью. Кардиология. 2019;59(2S):31-9.

Vinogradova NG. City Center for the Treatment of Chronic Heart Failure: the organization of work and the effectiveness of treatment of patients with chronic heart failure. Kardiologiia. 2019;59(2S):31-9. (In Russ.)

500

Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010; (8):CD007228.

501

Koehler F, Winkler S, Schieber M, et al. Telemedial interventional monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure. Eur J Heart Fail. 2010;12:1354-62.

502

Jack BW, Chetty VK, Anthony D, et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150(3):178-87.

503

Linden A, Butterworth S. A comprehensive hospital-based intervention to reduce readmissions for chronically ill patients: a randomized controlled trial. Am J Manag Care. 2014;20(10): 783-92.

504

Wakefield BJ, Boren SA, Groves PS, Conn VS. Heart failure care management programs: a review of study interventions and meta-analysis of outcomes. J Cardiovasc Nurs. 2013;28(1):8-19.

505

Van Spall HGC, Lee SF, Xie F, et al. Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. The PACT-HF Randomized Clinical Trial. JAMA. 2019;321(8):753-61. doi:10.1001/jama.2019.0710.

506

Sochalski J, Jaarsma T, Krumholz HM, et al. What works in chronic care management: the case of heart failure? Health Aff (Millwood). 2009;28:179-89.

507

Van Spall HGC, Rahman T, Mytton O, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail. 2017;19(11):1427-43.

508

Masoudi FA. A Transitional-Care Model to Reduce Readmissions After Heart Failure? JAMA. 2019;321: doi:10.1001/jama.2019.0710.

509

Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol. 2002;39:83-9.

510

Stewart S, Horowitz JD. Home-based intervention in congestive heart failure: long-term implications on readmission and survival. Circulation. 2002;105:2861-6.

511

Беленков Ю.Н., Агеев Ф. Т., Банщиков Г. Т. и др. Влияние специализированных форм активного амбулаторного ведения на функциональный статус, качество жизни и показатели гемодинамики больных с выраженной сердечной недостаточностью. Результаты Российской программы “Шанс”. Сердечная недостаточность. 2007;3:112-6.

Belenkov YuN, Ageev FT, Banshchikov GT, et al. Influence of specialized forms of active ambulatory management on functional status, quality of life and hemodynamic parameters of patients with severe heart failure. The results of the Russian program “Chance”. Serdechnaya nedostatochnost'. 2007;8(3):112-6. (In Russ.)

512

Фомин И. В., Виноградова Н. Г. Организация специализированной медицинской помощи больным с хронической сердечной недостаточностью. CardioCoMaTUka. 2017;8(3):10-5.

Fomin IV, Vinogradova NG. Organization of specialized medical care for patients with chronic heart failure. Cardiosomatics. 2017;8(3):10-5. (In Russ.)

513

Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007;154(2):260-6. doi:10.1016/j. ahj. 2007.01.041.

514

Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-17. doi:10.1093/eurjhf/hft050.

515

Fonarow G, Stough W, Abraham W, et al. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure. Journal of the American College of Cardiology. 2007;50(8):768-77. doi:10.1016/j.jacc.2007.04.064.

516

Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One. 2013;8:e72476. doi:10.1371/journal.pone.0072476.

517

Fonarow GC, Abraham WT, Albert NM, et al. Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes. Findings From OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-54. doi:10.1001/archinte.168.8.847.

518

Sandoval C, Walter SD, Krueger P, et al. Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure. Epidemiol Infect. 2007;135:574-82. doi:10.1017/S095026880600714X.

519

Vardeny O, Claggett B, Udell JA, et al; PARADIGM-HF Investigators. Influenza vaccination in patients with chronic heart failure: the PARADIGM-HF trial. JACC Heart Fail. 2016; 4:152-8. doi:10.1016/j.jchf.2015.10.012.

520

Mohseni H, Kiran A, Khorshidi R, Rahimi K. Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study. Eur Heart J. 2017; 38:32633. doi:10.1093/eurheartj/ehw411.

521

Kopel E, Klempfner R, Goldenberg I. Influenza vaccine and survival in acute heart failure. Eur J Heart Fail. 2014;16:264-70. doi:10.1002/ejhf.14.

522

Modin D, Jorgensen ME, Gislason G, et al. Influenza vaccine in heart failure: cumulative number of vaccinations, frequency, timing, and survival: a Danish Nationwide Cohort Study. Circulation. 2019:139:575-89. doi:10.1161/CIRCULATIONAHA.118.036788.

523

Antunes MM, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. European Heart Journal — Quality of Care and Clinical Outcomes, qcaa030, doi:10.1093/ehjqcco/qcaa030.

524

Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310(9):563-72.

525

Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 1984;310(6):347-52.

526

Van den Ouweland FA, Gribnau FW, Meyboom RH Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly Age Ageing. 1988;17(1):8-16

527

Ungprasert P, Srivali N, Thongprayoon C. Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies Clin Cardiol. 2016;39(2):111-8.

528

Doukky R, Avery E, Mangla A, et al. Impact of Dietary Sodium Restriction on Heart Failure Outcomes. JACC: Heart Failure. 2016;4 (1):24-35. doi:10.1016/j.jchf.2015.08.007.

529

Paterna S, Gaspare P, Fasullo S, et al. Normal sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clinical Science. 2008;114(3):221-30. doi:10.1042/CS2007019.

530

De Vecchis R, Paccone A, Di Maio M. Effects of a Restricted Water Intake on Various Clinical and Laboratory Outcomes in Patients With Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Minerva Cardioangiol. 2020; doi: 10.23736/S0026-4725.20.05072-0. Online ahead of print.

531

Walsh CR, Larson MG, Evans JC, et al. Alcohol Consumption and Risk for Congestive Heart Failure in the Framingham Heart Study. Annals of Internal Medicine. 2002;136(3):181. doi:10.7326/0003-4819-136-3-200202050-00005.

532

Harjola VP, Mullens W, Banaszewski M, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. Eur J Heart Fail. 2017;19:821-36.

533

Bjork JB, Alton KK, Georgiopoulou VV, et al. Defining advanced heart failure: a systematic review of criteria used in clinical trials. J Card Fail. 2016;22:569-77.

534

Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-804.

535

Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. 1991;90:353-9.

536

Hummel YM, Liu LCY, Lam CS, et al. Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. Eur J Heart Fail. 2017;19:1651-60.

537

Quinones MA, Greenberg BH, Kopelen HA, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 2000;35:1237-44.

538

Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan Heart Failure Trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol. 2004;43:1892-7.

539

Rossi A, Cicoira M, Bonapace S, et al. Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction. Heart. 2007;93:1420-5.

540

Paraskevaidis IA, Ikonomidis I, Simitsis P, et al. Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study. Eur J Heart Fail. 2017;19:846-61.

541

Lichtenstein D, Lascols N, Meziere G, Gepner A. Ultrasound diagnosis of alveolar consolidation in the critically ill. Intensive Care Med. 2004;30:276-81.

542

Platz E, Lewis EF, Uno H, et al. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. Eur Heart J. 2016;37:1244-51.

543

Wang NC, Maggioni AP, Konstam MA, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008;299:2656-66.

544

Hawkins NM, Wang D, McMurray JJ, et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart. 2007;93:59-64.

545

Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the HFA of the ESC, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544-58.

546

Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987-96.

547

Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833-8.

548

Perna ER, Macin SM, Canella JP, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation. 2004;110:2376-82.

549

Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008;101:231-7.

550

Peacock WFI, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117-26.

551

Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49:1943-50.

552

Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13:718-25.

553

Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol. 2008;101:29-38.

554

Santaguida PL, Don-Wauchope AC, Ali U, et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Fail Rev. 2014;19:507-19.

555

van Kimmenade RR, Pinto YM, Bayes-Genis A, et al. Usefulness of intermediate aminoterminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol. 2006;98:386-90.

556

Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-74.

557

Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-41.

558

Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328-33.

559

Stienen S, Salah K, Eurlings LW, et al. Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels? Eur J Heart Fail. 2015;17:936-44.

560

Park M, Sangean MC, Volpe MDS, et al. Randomized, prospective trial of oxygen, continuous positive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med. 2004;32:2407-415.

561

Park JH, Balmain S, Berry C, et al. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart. 2010;96:533-8.

562

Vital FMR, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2013;5:CD005351.

563

Weng C-L, Zhao Y-T, Liu Q-H, et al. Meta-analysis: noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med. 2010;152:590-600.

564

Gray AJ, Goodacre S, Newby DE, et al. A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO Trial. Health Technol Assess. 2009;13:1-106.

565

Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992;21:669-74.

566

Metra M, Felker GM, Zaca V, et al. Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. Int J Cardiol. 2010;144:175-9.

567

Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;8:CD005151.

568

Mordi IR, Santema BT, Kloosterman M, et al. Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clin Res Cardiol. 2019;108(7):797-805. doi:10.1007/s00392-018-1409-x.

569

Simpson J, Castagno D, Doughty RN, et al. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC metaanalysis. Eur J Heart Fail. 2015;17:1182-91.

570

Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J. 1995;16:521-8.

571

Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29:1149-53.

572

Clemo H, Wood M, Gilligan D, Ellenbogen K. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 1998;81:594-8.

573

Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2015;3:647-53.

574

Komajda M, Cowie MR, Tavazzi L, et al. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19:1414-23.

575

Voors AA, Ouwerkerk W, Zannad F, et al. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. Eur J Heart Fail. 2017;19:627-34.

576

Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003;92:1350-4.

577

Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients inhospital or early after discharge: Primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21(8):998-1007. doi:10.1002/ejhf.1498.

578

Adams KF, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for inhospital mortality in acutely decompensated heart failure classification and regression tree analysis. JAMA. 2015;293:572-80.

579

Thorvaldsen T, Benson L, Stahlberg M, et al. Triage of patients with moderate to severe heart failure: who should be referred to a heart failure center? J Am Coll Cardiol. 2014;63:661-71.

580

Jonkman NH, Westland H, Groenwold RH, et al. Do Self-Management Interventions Work in Patients With Heart Failure? An Individual Patient Data Meta-Analysis. Circulation. 2016;133:1189-98.

581

Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883-90.

582

Iakobishvili Z, Cohen E, Garty M, et al. Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care. 2011;13:76-80

583

Peacock WF, Hollander JE, Diercks DB, et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008;25:205-9.

584

Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-40.

585

Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.

586

Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527-34.

587

De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779-89.

588

Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-7.

589

Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103-11.

590

O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(1 Pt 1):78-86.

591

Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC Heart Fail. 2017;4:595-604.

592

Belletti A, Castro ML, Silvetti S, et al. The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth. 2015;115:656-75.

593

Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146:278-88.

594

Sintek MA, Gdowski M, Lindman BR, et al. Intra-aortic balloon counterpulsation in patients with chronic heart failure and cardiogenic shock: clinical response and predictors of stabilization. J Card Fail. 2015;21:868-76.

595

Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. N Engl J Med. 2017;376:451-60.

596

Mehra MR, Goldstein DJ, Uriel N, et al; MOMENTUM 3 Investigators. Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. N Engl J Med. 2018;378:1386-95.

597

John R, Long JW, Massey HT, et al. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg. 2011;141(4):932-9.

598

Riebandt J, Haberl T, Mahr S, et al. Preoperative patient optimization using extracorporeal life support improves outcomes of INTERMACS Level I patients receiving a permanent ventricular assist device. Eur J Cardiothorac Surg. 2014;46(3):486-92; discussion 492. doi:10.1093/ejcts/ezu093.

599

Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения хронической сердечной недостаточности. М.: Медиа Медика. 2000. 266 с.

Belenkov YuN, Mareev VYu. Principles of heart failure rational treatment. M.: Media Medica; 2000. 266 p. (In Russ.)

600

Guyatt GH, Thompson PJ, Berman LB, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132(8):919.

601

Enright PL. The six-minute walk test. Respir Care. 2003;48(8):783-5.

602

Faggiano P, D'Aloia A, Gualeni A, et al. The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature. Eur J Heart Fail. 2004;6(6):687-91.

603

Zielinska D, Bellwon J, Rynkiewicz A, Elkady MA. Prognostic value of the six-minute walk test in heart failure patients undergoing cardiac surgery: a literature review. Rehabil Res Pract. 2013; Article ID 965494. doi:10.1155/2013/965494.

604

Ingle L, Cleland JG, Clark AL. The long-term prognostic significance of 6-minute walk test distance in patients with chronic heart failure. Biomed Res Int. 2014;2014:505969.

605

Ingle L, Cleland JG, Clark AL. The relation between repeated 6-minute walk test performance and outcome in patients with chronic heart failure. Ann Phys Rehabil Med. 2014;57(4):244-53.

606

Pollentier B, Irons SL, Benedetto CM, et al. Examination of the six minute walk test to determine functional capacity in people with chronic heart failure: a systematic review. Cardiopulm Phys Ther J. 2010;21(1):13-21.

607

Palau P, Dommguez E, Nunez E, et al. Six-minute walk test in moderate to severe heart failure with preserved ejection fraction: useful for functional capacity assessment? Int J Cardiol. 2016;203:800-2.

608

Forman DE, Fleg JL, Kitzman DW, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol. 2012;60(25):2653-61.

609

Kaminsky LA, Tuttle MS. Functional assessment of heart failure patients. Heart Fail Clin. 2015;11(1):29-36.

The authors declare that there are no conflicts of interest present.